DBD
Diebold Nixdorf, Incorporated
DBD's outlook is improving, though it still trails on the overall score.
NVDA
NVIDIA Corporation
NVDA has the edge over DBD overall, supported by stronger valuation and stronger modeled upside.
DBD Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Stable | |
| Stable |
DBD's profitability is currently healthy, and its revenue, cash flow and balance sheet are stable.
NVDA Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Strong | |
| Strong | |
| Strong |
NVDA's revenue, profitability, cash flow and balance sheet are all currently strong.
DBD PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 0.7x | $1.54 | -97% |
| Forward | 9.8x | $54.75 | — |
| Fair | 22x | $44.94 | -18% |
| Current | 26x | $54.75 | — |
| Expensive | 32x | $67.83 | +24% |
Historical ranges are pointers, not guarantees.
DBD's PE is in its fair range at 26x. If earnings grow as analysts expect, today's price would be 9.8x next year's earnings.
NVDA PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $166 | — |
| Current | 21x | $166 | — |
| Cheap | 44x | $345 | +108% |
| Fair | 65x | $511 | +207% |
| Expensive | 93x | $734 | +342% |
Historical ranges are pointers, not guarantees.
NVDA has the edge over DBD in the historical PE scenario, which offers more potential upside but is not a forecast.
DBD Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Improving | |
| Limited | |
| High |
Analysts expect DBD's earnings to grow and its profitability to improve, with its revenue holding steady.
NVDA Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Weakening | |
| Broad | |
| Moderate |
Analysts expect strong earnings and revenue growth for NVDA, but weaker profitability.
DBD Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $5.56 | +166% |
| Q3 2026 | $2.09 | +53% |
| Q2 2026 | $3.01 | +$3.35 |
| Q1 2026 | $2.90 | +$3.17 |
| Q4 2025 | $2.54 | +$2.98 |
| Q3 2025 | $1.37 | +$1.37 |
| Q2 2025 | -$0.34 | -101% |
| Q1 2025 | -$0.27 | -101% |
| Q4 2024 | -$0.44 | -101% |
DBD's earnings per share have fallen from their peak: $2.09 over the past year, against $57.03 in mid-2024.
NVDA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $13.77 | +74% |
| Q3 2026 | $7.91 | +125% |
| Q2 2026 | $6.53 | +111% |
| Q1 2026 | $4.90 | +67% |
| Q4 2025 | $4.03 | +59% |
| Q3 2025 | $3.51 | +65% |
| Q2 2025 | $3.10 | +81% |
| Q1 2025 | $2.94 | +147% |
| Q4 2024 | $2.54 | +234% |
NVDA has the edge over DBD on earnings, with more consistent year-over-year improvement.
DBD Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $994.3M | +5.2% |
| Q2 2026 | $930.8M | +1.7% |
| Q1 2026 | $891.8M | +6% |
| Q4 2025 | $1.1B | +12% |
| Q3 2025 | $945.2M | +2% |
| Q2 2025 | $915.2M | -2.6% |
| Q1 2025 | $841.1M | -6.1% |
| Q4 2024 | $988.9M | -4.6% |
DBD's revenue has grown year over year for five quarters in a row: $994M last quarter, up 5.2% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.9% | -3.9 points |
| Q2 2026 | 6.2% | 0 points |
| Q1 2026 | 3.7% | +0.1 points |
| Q4 2025 | 7.5% | +3.3 points |
| Q3 2025 | 7.8% | +2.8 points |
| Q2 2025 | 6.1% | -1.4 points |
| Q1 2025 | 3.5% | +0.9 points |
| Q4 2024 | 4.2% | -1.2 points |
DBD's operating margin was 3.9% last quarter, down 3.9 points from the same quarter a year ago.
NVDA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $96.2B | +106% |
| Q2 2026 | $81.6B | +85% |
| Q1 2026 | $68.1B | +73% |
| Q4 2025 | $57B | +62% |
| Q3 2025 | $46.7B | +56% |
| Q2 2025 | $44.1B | +69% |
| Q1 2025 | $39.3B | +78% |
| Q4 2024 | $35.1B | +94% |
NVDA has the edge over DBD on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 66% | +5.4 points |
| Q2 2026 | 66% | +17 points |
| Q1 2026 | 65% | +3.9 points |
| Q4 2025 | 63% | +0.8 points |
| Q3 2025 | 61% | -1.2 points |
| Q2 2025 | 49% | -16 points |
| Q1 2025 | 61% | -0.5 points |
| Q4 2024 | 62% | +4.9 points |
NVDA has the edge over DBD on profitability, with a higher operating margin.
DBD Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$47.4M | -227% |
| Q2 2026 | -$13.6M | -145% |
| Q1 2026 | $31.7M | +102% |
| Q4 2025 | $217.5M | +11% |
| Q3 2025 | $37.4M | +$52.9M |
| Q2 2025 | $30.1M | +$38.1M |
| Q1 2025 | $15.7M | +$39.2M |
| Q4 2024 | $196.2M | +26% |
DBD has burned cash in most quarters: $188M over the past year, down 33% from the year before.
NVDA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $21.4B | +59% |
| Q2 2026 | $48.6B | +86% |
| Q1 2026 | $34.9B | +124% |
| Q4 2025 | $22.1B | +32% |
| Q3 2025 | $13.5B | -0.3% |
| Q2 2025 | $26.2B | +75% |
| Q1 2025 | $15.6B | +38% |
| Q3 2024 | $13.5B | +113% |
NVDA has the edge over DBD on cash flow, with more consistent year-over-year improvement.
DBD Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -2% | -700K shares |
| 1 year | -6.5% | -2.4M shares |
| 3 years | -7.9% | -3M shares |
| 5 years | -56% | -43.7M shares |
| Available history | -55% | -42.2M shares |
DBD has the edge over NVDA on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $33.9M |
| Q2 2026 | $60.6M |
| Q1 2026 | $60.4M |
| Q4 2025 | $51.1M |
| Q3 2025 | $39.9M |
| Q2 2025 | $30.1M |
| Q1 2025 | $9.6M |
| Q4 2024 | $2.3M |
DBD spent $206M buying back its own shares over the past year, up 152% from the year before.
NVDA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -106M shares |
| 1 year | -1% | -247M shares |
| 3 years | -2.8% | -705M shares |
| 5 years | -4.1% | -1B shares |
| Available history | -1.8% | -435M shares |
NVDA has 24.3B diluted shares, down 1% from a year ago, with $55.3B in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q3 2026 | $19.7B |
| Q2 2026 | $19.3B |
| Q1 2026 | $3.8B |
| Q4 2025 | $12.5B |
| Q3 2025 | $9.7B |
| Q2 2025 | $14.1B |
| Q1 2025 | $7.8B |
| Q4 2024 | $11B |
NVDA spent $55.3B buying back its own shares over the past year, up 30% from the year before.
DBD Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 2.3x | Moderate |
| Q2 2026 | 1.8x | Healthy |
| Q1 2026 | 1.5x | Healthy |
| Q4 2025 | 1.5x | Healthy |
| Q3 2025 | 2.2x | Moderate |
| Q2 2025 | 2.5x | Moderate |
| Q1 2025 | 2.7x | Moderate |
| Q4 2024 | 2.8x | Moderate |
DBD's net debt is about 2.3 years of its operating earnings (EBITDA), about the same as a year ago.
NVDA Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.1x | Very low |
| Q2 2026 | -0.0x | Net Cash |
| Q1 2026 | -0.0x | Net Cash |
| Q4 2025 | -0.0x | Net Cash |
| Q3 2025 | -0.0x | Net Cash |
| Q2 2025 | -0.1x | Net Cash |
| Q1 2025 | -0.0x | Very low |
| Q4 2024 | -0.0x | Net Cash |
NVDA has the edge over DBD on leverage, with a lower net debt burden relative to earnings.
DBD Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 34.8 | Neutral |
| Stochastic | 11.4 | Oversold |
DBD's weekly RSI is 35 (neutral) and its Stochastic is 11 (oversold).
NVDA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 33.4 | Neutral |
| Stochastic | 18.1 | Oversold |
NVDA's weekly RSI is 33 (neutral) and its Stochastic is 18 (oversold).
DBD PE vs Technology Sector
| Metric | DBD | Sector median | Relative |
|---|---|---|---|
| PE | 26x | 28x | 6% below |
| PE % | 61 | 25 | 36 pts above |
DBD is trading at 26x earnings, in line with the Technology sector's median of 28x.
NVDA PE vs Technology Sector
| Metric | NVDA | Sector median | Relative |
|---|---|---|---|
| PE | 21x | 28x | 25% below |
| PE % | 0 | 35 | 35 pts below |
NVDA has the edge over DBD on valuation relative to its sector.
DBD Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $61.8 | 11% below |
| 20 week MA | $69.7 | 21% below |
| 50 week MA | $73.3 | 25% below |
| 100 week MA | $62.4 | 12% below |
NVDA has stronger trend alignment. DBD is above 0 of 4 weekly averages versus NVDA above 1 of 5.
NVDA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $208.9 | 20% below |
| 20 week MA | $212.0 | 22% below |
| 50 week MA | $199.9 | 17% below |
| 100 week MA | $175.1 | 5.1% below |
| 200 week MA | $123.6 | 34% above |
NVDA has fallen below most of its moving averages, though it's still 34% above its 200-week average.
DBD Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2023 | $20.1 | $29.0 | +44% |
| 2024 | $29.0 | $42.9 | +48% |
| 2025 | $42.9 | $69.3 | +61% |
| 2026 YTD | $69.3 | $54.8 | -21% |
DBD has finished every year since 2023 higher, and it's down 21% so far in 2026.
NVDA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $5.92 | $13.0 | +119% |
| 2021 | $13.0 | $29.6 | +128% |
| 2022 | $29.6 | $15.2 | -49% |
| 2023 | $15.2 | $49.5 | +226% |
| 2024 | $49.5 | $137.0 | +177% |
| 2025 | $137.0 | $190.5 | +39% |
| 2026 YTD | $190.5 | $166.2 | -13% |
NVDA has the edge over DBD on returns for 2026, with the stronger performance.